Nektar Therapeutics cash flow to debt ratio of -140.03% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Nektar Therapeutics's free cash flow has decreased 17.78% from $-177.18M last year to $-208.68M, signaling decreasing performance

Nektar Therapeutics's debt to equity ratio is 0.25, which means that the company's assets are healthy financed, signaling financial stability.

Nektar Therapeutics's debt has decreased relative to shareholder equity from 1.69 last year to 0.25 today, signaling strengthened financials

Nektar Therapeutics has a net cash position, so leverage is healthy.

Nektar Therapeutics's interest coverage ratio is -4.29, which means that the company struggles to meet interest obligations, signaling financial risk.

Nektar Therapeutics's profit margin has decreased (135.13%) in the last year from -120.86% to -284.18%, signaling decreasing performance

Nektar Therapeutics's short-term assets of $266.27M exceed its short-term liabilities of $53.54M

Nektar Therapeutics's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Nektar Therapeutics's return on equity of -87.00%, is lower than 15.00%, indicating bad performance

Nektar Therapeutics's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Nektar Therapeutics had positive net income in only 0 out of 5 years, indicating unstable earnings

Nektar Therapeutics has negative free cash flow, indicating the company is burning cash rather than generating it

Nektar Therapeutics has negative free cash flow, indicating cash burn

Nektar Therapeutics's yearly earnings has decreased 37.92% since last year from $-118.96M to $-164.08M, signaling decreasing performance

Nektar Therapeutics's yearly revenue has decreased 43.89% since last year from $98.43M to $55.23M, signaling decreasing performance

ROIC -17.17% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Nektar Therapeutics's 3-year revenue CAGR of -15.66% is negative, indicating declining revenue over the past 3 years

Nektar Therapeutics had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Nektar Therapeutics had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Nektar Therapeutics has insufficient data to evaluate this check.

Nektar Therapeutics has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nektar Therapeutics is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Nektar Therapeutics has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Nektar Therapeutics is overvalued relative to its fair value price of -52.05 based on Earnings Fair Value model

Nektar Therapeutics has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nektar Therapeutics has a price-to-book ratio of 3.21x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Nektar Therapeutics has a price-to-sales ratio of 33.28x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue